Niosomes Containing Isomeldenin Plus Lupeol Induce Apoptosis of SK-OV-3, MCF-7, and 3SKBr Cell Lines and Alter the Expression of Apoptotic Genes
محورهای موضوعی :
Alaa Naseer M. Ali
1
,
Hadeel A. Omear
2
,
Shiama Rabeea Banoon
3
,
Abdolmajid Ghasemian
4
,
M.A. Abdelzaher
5
1 - Department of Biology, University of Mustansyria, Baghdad, Iraq
2 - College of Science, Tikrit University, Iraq
3 - Department of Biology, College of Science, University of Misan, Misan, Iraq
4 - Noncommunicable diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
5 - Environmental Science and Industrial Development Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef 62511, Egypt
کلید واژه: Bioactive compounds, Nanoniosomes, Isomeldenin, Lupeol, Cancer cell lines, Apoptotic genes,
چکیده مقاله :
Cancer treatment is a concern due to side effects, the resistance of tumor cells, and costs. Application of alternative compounds particularly delivered by nanocarriers is a paramount approach for the efficient treatment of cancer cells. Our objective was to kill ovary and breast cancer cells using nanoniosomes containing isomeldenin plus lupeol. Herein, nanoniosomes were synthesized using the thin-layer hydration method and their physical and chemical traits were assessed using scanning electron microscopy (SEM) and Dynamic Light Scattering (DLS) analysis. The dialysis bag was also used the entrapment rate and release pattern. Various concentrations of lupeol and isomeldenin were prepared for the assessment of anticancer effects against ovary and breast cancer cells (SK-OV-3, MCF-7, and 3SKBr cell lines) using the MTT assay and gene expression. The results were compared to each bioactive compound singly and free forms of them. The expression of Bax and Bcl2 genes was examined at low concentrations of each isomeldenin and lupeol (25µg mL-1) singly and in combination with gemcitabine (25µg mL-1). The size of synthesized nanoniosomes included 203.2 nm size and the entrapment rate was 72.6%. The death rate of SK-OV-3 in exposure to isomeldenin (100 µg mL-1) included 76.34% and for MCF-7 and 3SKBr cell lines included 64.66% and 62.99%, respectively. The lupeol (100µg mL-1) killing rate against SK-OV-3, MCF-7, and 3SKBr cell lines respectively included 42.36%, 40.26%, and 39.96%. The nanoniosomes containing isomeldenin killed SK-OV-3, MCF-7, and 3SKBr cell lines at 89.6%, 78.3%, and 69.6%, respectively. Moreover, nanoniosomes containing lupeol killed SK-OV-3, MCF-7, and 3SKBr cell lines at 88.9%, 79.2%, and 66.9%, respectively. The expression of the Bax gene was decreased 3.2 fold and the Bcl2 gene was increased 2.6 fold in exposure to nanoniosomes containing both gemcitabine and lupeol being significantly higher than those of control. The combination of each isomeldenin and lupeol with gemcitabine significantly increased the death of ovary and breast cancer cells in niosomal form. Herbal bioactive compounds nano-formulation is promising for cancer therapy.
Cancer treatment is a concern due to side effects, the resistance of tumor cells, and costs. Application of alternative compounds particularly delivered by nanocarriers is a paramount approach for the efficient treatment of cancer cells. Our objective was to kill ovary and breast cancer cells using nanoniosomes containing isomeldenin plus lupeol. Herein, nanoniosomes were synthesized using the thin-layer hydration method and their physical and chemical traits were assessed using scanning electron microscopy (SEM) and Dynamic Light Scattering (DLS) analysis. The dialysis bag was also used the entrapment rate and release pattern. Various concentrations of lupeol and isomeldenin were prepared for the assessment of anticancer effects against ovary and breast cancer cells (SK-OV-3, MCF-7, and 3SKBr cell lines) using the MTT assay and gene expression. The results were compared to each bioactive compound singly and free forms of them. The expression of Bax and Bcl2 genes was examined at low concentrations of each isomeldenin and lupeol (25µg mL-1) singly and in combination with gemcitabine (25µg mL-1). The size of synthesized nanoniosomes included 203.2 nm size and the entrapment rate was 72.6%. The death rate of SK-OV-3 in exposure to isomeldenin (100 µg mL-1) included 76.34% and for MCF-7 and 3SKBr cell lines included 64.66% and 62.99%, respectively. The lupeol (100µg mL-1) killing rate against SK-OV-3, MCF-7, and 3SKBr cell lines respectively included 42.36%, 40.26%, and 39.96%. The nanoniosomes containing isomeldenin killed SK-OV-3, MCF-7, and 3SKBr cell lines at 89.6%, 78.3%, and 69.6%, respectively. Moreover, nanoniosomes containing lupeol killed SK-OV-3, MCF-7, and 3SKBr cell lines at 88.9%, 79.2%, and 66.9%, respectively. The expression of the Bax gene was decreased 3.2 fold and the Bcl2 gene was increased 2.6 fold in exposure to nanoniosomes containing both gemcitabine and lupeol being significantly higher than those of control. The combination of each isomeldenin and lupeol with gemcitabine significantly increased the death of ovary and breast cancer cells in niosomal form. Herbal bioactive compounds nano-formulation is promising for cancer therapy.
1. Cohen S.Y., Stoll C.R., Anandarajah A., Doering M., Colditz G.A., 2023. Modifiable risk factors in women at high risk of breast cancer: a systematic review. Breast Cancer Research. 25(1),1-20.
2. Berek J.S., Renz M., Kehoe S., Kumar L., Friedlander, M., 2021. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology & Obstetrics. 155, 61-85.
3. Waks A.G., Winer E.P., 2019. Breast cancer treatment: a review. Jama. 321(3), 288-300.
4. Lü J.M., Lin P.H., Yao Q., Chen C., 2010. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. Journal of cellular and molecular medicine. 14(4), 840-860.
5. Al-Mhanaa H.A.H., Al-Obaidi A.B., Algazali S.A., Abdelzaher H.G., Abdelzaher M.A., Alsirhani A.M., Mohammed R.M., Mohammed R., Ali M.K., Mahdi M.Q.S., Abdul-Jawad D.H., 2024. Study the Correlation of Ochratoxin A with a Prevalence of Breast Cancer in Al-Najaf Province, Iraq. Medical Journal of Babylon. 21(Suppl 1), S141-S144.
6. Nath A., Mitra S., Mistry T., Pal R., Nasare V.D., 2022. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer. Medical Oncology. 39,1-33.
7. Hope A., Wade S.J., Aghmesheh M., Vine K.L., 2022. Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. Journal of Controlled Release. 341, 399-413.
8. Fayed, A.M., Abdelzaher, M.A., Mahdi, N.H., AlKhafaf, D.M., AbdElRahman, M., Aldhalmi, A.K., Al-Qaim, Z.H., Abdelzaher, H.G., Alsirhani, A.M. and Morsi, S.E.S., 2024. Effect of ginger, chamomile, and green tea extracts on prostate cancer cells. Journal of Genetic Engineering and Biotechnology, 22(3), p.100395.
9. Banoon, S.R. and Ghasemian, A., 2022. The Characters of Graphene Oxide Nanoparticles and Doxorubicin Against HCT-116 Colorectal Cancer Cells In Vitro. Journal of gastrointestinal cancer, 53(2), pp.410-414.
10. Zarenezhad E., Kanaan M.H.G., Abdollah S.S., Vakil M.K., Marzi M., Mazarzaei A., Ghasemian A., 2023.
Metallic Nanoparticles: Their Potential Role in Breast Cancer Immunotherapy via Trained Immunity Provocation. Biomedicines. 11(5),1245.
11. Bahmanyar M., Vakil M.K., Al-Awsi G.R.L., Kouhpayeh S.A., Mansoori Y., Mansoori B., Moravej A., Mazarzaei A., Ghasemian A., 2022. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment. BMC cancer. 22(1), 1220.
12. Chakraborty S., Rahman T., 2012. The difficulties in cancer treatment. Ecancermedicalscience. 6: ed16.
13. Gyanani V., Haley J.C., Goswami R., 2021. Challenges of current anticancer treatment approaches with a focus on liposomal drug delivery systems. Pharmaceuticals. 14(9), 835.
14. Gupta V., Mohapatra S., Mishra H., Farooq U., Kumar K., Ansari M.J., Aldawsari M.F., Alalaiwe A.S., Mirza M.A., Iqbal Z., 2022. Nanotechnology in cosmetics and cosmeceuticals—a review of latest advancements. Gels 8(3), 173.
15. Hassan S.A.D.H., Almaliki M.N.S., Hussein Z.A., Albehadili H.M., Banoon S.R., Al-Abboodi A., Al-Saady M., 2023. Development of Nanotechnology by Artificial Intelligence: A Comprehensive Review. Journal of Nanostructures. 13(4), 915-932.
16. Dang Y., Guan J., 2020. Nanoparticle-based drug delivery systems for cancer therapy. Smart Materials in Medicine. 1,10-19.
17. Wang X., Li C., Wang Y., Chen H., Zhang X., Luo C., Zhou W., Li L., Teng L., Yu H., Wang J., 2022. Smart drug delivery systems for precise cancer therapy. Acta Pharmaceutica Sinica B. 12(11), 4098-4121.
18. Al-Thakafy N.T., Abdelzaher M.A., Abdelzaher H.G., Saleh M.Y., Al-Enizzi M.S., Saied S.M., Elbagory M., El-Nahrawy S., Omara A.E.D., Al-Shalawi M., Moghanm F.S., 2024. A novel chalcone compound as a reagent for the validation of pharmaceutical cefotaxime sodium preparations. Results in Chemistry.101387.
19. Chehelgerdi M., Chehelgerdi M., Allela O.Q.B., Pecho R.D.C., Jayasankar N., Rao D.P., Thamaraikani T., Vasanthan M., Viktor P., Lakshmaiya N., Saadh M.J., 2023. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Molecular cancer. 22(1), 169.
20. Bhardwaj P., Tripathi P., Gupta R., Pandey S., 2020. Niosomes: A review on niosomal research in the last decade. Journal of Drug Delivery Science and Technology. 56, 101581.
21. Izhar M.P., Hafeez A., Kushwaha P., Simrah, 2023. Drug Delivery Through Niosomes: A Comprehensive Review with Therapeutic Applications. Journal of Cluster Science. 34(5), 2257-2273.
22. Witika B.A., Bassey K.E., Demana P.H., Siwe-Noundou X., Poka, M.S., 2022. Current advances in specialised niosomal drug delivery: Manufacture, characterization and drug delivery applications. International journal of molecular sciences. 23(17), 9668.
23. Bartelds R., Nematollahi M.H., Pols T., Stuart M.C., Pardakhty A., Asadikaram G., Poolman, B., 2018. Niosomes, an alternative for liposomal delivery. PLoS One. 13(4), e0194179.
24. Monjazeb Marvdashti L., Arab S., Bahraminasab M., Roustaei M., Souri S., Heydari Majd M., Abdolshahi A., 2023. Smirnovia iranica whole herb extract: antioxidant, radical scavenging, anti-microbial and anti-cancer effects. Journal of Chemical Health Risks. 13(2), 391-400.
25. Kamran S., Sinniah A., Abdulghani M.A., Alshawsh M.A., 2022. Therapeutic potential of certain terpenoids as anticancer agents: a scoping review. Cancers. 14(5), 1100.
26. Kłos P., Chlubek D., 2022. Plant-derived terpenoids: a promising tool in the fight against melanoma. Cancers. 14(3), 502.
27. Liu K., Zhang X., Xie L., Deng M., Chen H., Song J., Long J., Li X., Luo J., 2021. Lupeol and its derivatives as anticancer and anti-inflammatory agents: Molecular mechanisms and therapeutic efficacy. Pharmacological research. 164, 105373.
28. Pitchai D., Roy A., Ignatius C., 2014. In vitro evaluation of anticancer potentials of lupeol isolated from Elephantopus scaber L. on MCF-7 cell line. Journal of advanced pharmaceutical technology & research. 5(4), 179-184.
29. Mirzaei-Parsa M.J., Najafabadi M.R.H., Haeri A., Zahmatkeshan M., Ebrahimi S.A., Pazoki-Toroudi H., Adel M., 2020. Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer. Breast Cancer. 27, 243-251.
30. Ali A., Banerjee S., Kamaal S., Usman M., Das N., Afzal M., Alarifi A., Sepay N., Roy P., Ahmad M., 2021. Ligand substituent effect on the cytotoxicity activity of two new copper (ii) complexes bearing 8-hydroxyquinoline derivatives: Validated by MTT assay and apoptosis in MCF-7 cancer cell line (human breast cancer). RSC advances 11(24),14362-14373.
31. Oreshko A.S., Rodnyy A.Y., Bazovkina D.V., Naumenko V.S., 2023. Effects of central administration of the human Tau protein on the Bdnf, Trkb, p75, Mapt, Bax and Bcl-2 genes expression in the mouse brain. Vavilov Journal of Genetics and Breeding. 27(4), 342.
32. Li J., Wang R., Gao J., 2021. Novel anticancer drugs approved in 2020. Drug Discoveries & Therapeutics. 15(1), 44-47.
33. Allison S.J., 2022. Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism (s) of Action. Biomedicines. 10(8), 1767.
34. Patil M., Hussain A., Altamimi M.A., Ashique S., Haider N., Faruk A., Khuroo T., Sherikar A., Siddique M.U.M., Ansari A., Barbhuiya T.K., 2023. An insight of various vesicular systems, erythrosomes, and exosomes to control metastasis and cancer. Advances in Cancer Biology-Metastasis. 100103.
35. Chen D., Liu X., Tian J., 2023. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Frontiers in Pharmacology. 14, 1111991.
36. Esmeeta A., Adhikary S., Dharshnaa V., Swarnamughi P., Maqsummiya Z.U., Banerjee A., Pathak S., Duttaroy, A.K., 2022. Plant-derived bioactive compounds in colon cancer treatment: An updated review. Biomedicine & Pharmacotherapy. 153, 113384.
37. Shrihastini V., Muthuramalingam P., Adarshan S., Sujitha M., Chen J.T., Shin H., Ramesh M., 2021. Plant derived bioactive compounds, their anti-cancer effects and in silico approaches as an alternative target treatment strategy for breast cancer: An updated overview. Cancers. 13(24), 6222.
38. Purohit S.J., Tharmavaram M., Rawtani D., Prajapati P., Pandya H., Dey, A., 2022. Niosomes as cutting edge nanocarrier for controlled and targeted delivery of essential oils and biomolecules. Journal of Drug Delivery Science and Technology. 73, 103438.
39. Moammeri A., Chegeni M.M., Sahrayi H., Ghafelehbashi R., Memarzadeh F., Mansouri A., Akbarzadeh I., Hejabi F., Abtahi M.S., Ren, Q., 2023. Current advances in niosomes applications for drug delivery and cancer treatment. Materials Today Bio. 100837.
40. Raeiszadeh M., Pardakhty A., Sharififar F., Mehrabani M., Mehrabani M., 2018. Phytoniosome: a novel drug delivery for myrtle extract. Iranian Journal of Pharmaceutical Research: IJPR. 17(3), 804.
41. Obeid M.A., Gany S.A.S., Gray A.I., Young L., Igoli J.O., Ferro, V.A., 2020. Niosome-encapsulated balanocarpol: compound isolation, characterisation, and cytotoxicity evaluation against human breast and ovarian cancer cell lines. Nanotechnology. 31(19), 195101.
42. Barani M., Mirzaei M., Torkzadeh-Mahani M., Nematollahi, M.H., 2018. Lawsone-loaded Niosome and its antitumor activity in MCF-7 breast Cancer cell line: a Nano-herbal treatment for Cancer. DARU Journal of Pharmaceutical Sciences. 26, 11-17.
43. Baranei M., Taheri R.A., Tirgar M., Saeidi A., Oroojalian F., Uzun L., Asefnejad A., Wurm F.R., Goodarzi V., 2021. Anticancer effect of green tea extract (GTE)-Loaded pH-responsive niosome Coated with PEG against different cell lines. Materials Today Communications. 26, 101751.
44. Hajizadeh M.R., Parvaz N., Barani M., Khoshdel A., Fahmidehkar M.A., Mahmoodi M., Torkzadeh-Mahani M., 2019. Diosgenin-loaded niosome as an effective phytochemical nanocarrier: Physicochemical characterization, loading efficiency, and cytotoxicity assay. DARU Journal of Pharmaceutical Sciences. 27, 329-339.
45. Elgqvist J., 2017. Nanoparticles as theranostic vehicles in experimental and clinical applications—focus on prostate and breast cancer. International Journal of Molecular Sciences. 18(5), 1102.
46. Dabaghian Amiri A., Mirzaie A., Ali Asgari E., Mahmoudzadeh A., 2021. Preparation of niosome loaded Artemisia chamamelifolia extract: antibacterial and anti-cancer activities and apoptosis gene expression analysis in breast cancer cell line (MCF-7). Feyz Medical Sciences Journal. 25(2), 839-849.
47. Banoon S.R., Jasim S.A., Ghasemian A., 2023. Effect of 12-week Aerobic Exercise on the Tumor Size and Expression of HIF-1α, BCL-2, Mir-15a, and VEGF Genes in BALB/C Female Mice with Breast Cancer. Journal of Chemical Health Risks. 13(2), 283-290.
